Tissue Genesis has been working with a range of world-class researchers, physicians, government agencies, and licensees to establish and fulfill the significant potential that adipose-derived cell therapy has to change the practice of medicine. Tissue Genesis' objectives include:

• Expanding the company's strong relationships with the U.S. Department of Defense in work related to government contracts. Tissue Genesis will also continue working towards establishing additional government-supported contract work and collaborating with various renowned researchers to further explore Tissue Genesis' technology and cell therapy applications.

• Collaborate with researchers and physicians to advance Tissue Genesis' technology from pre-clinical to clinical applications.

• Continue working with current licensees, such as SpineSmith, LP and Bioheart, Inc., to expand their work with human clinical applications of Tissue Genesis' products.

• Seek additional human clinical applications of Tissue Genesis' cell therapy to establish new cellular medical therapies.

• Encourage possible aesthetics market opportunities through a human clinical study of Tissue Genesis' technology in Japan. The clinical data generated will be used to expand the aesthetics and reconstructive opportunities in overseas markets.

• Continue development efforts of Tissue Genesis' technology in the veterinary market, such as the company's arangement with Canine Health Institute to exclsuively serve the campanion dog market in the Houston area, which will allow the company to make a strong entry into the veterinary industry.

• Continue to collaborate with appropriate entities with expertise in therapeutic areas, which will accelerate new clinical cellular therapeutic development utilizing Tissue Genesis' technology.

• Continue ongoing development efforts for the next-generation of the Tissue Genesis Cell Isolation System, to allow for additional application opportunities.